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1. Introduction  
Anemia is one of the leading causes of morbidity in chronic renal failure.1 Chronic kidney 
disease (CKD) associated anemia is largely due to reduced erythropoietin (EPO) release and, 
to a lesser degree, to shortened red cell survival.2 To overcome EPO deficiency in this 
population, the development and administration of erythropoiesis-stimulating agents 
(ESAs) such as recombinant human EPO and darbepoetin alfa (DPO) has resulted in 
substantial health benefits, including improved quality of life, reduced blood transfusion 
requirements, decreased left ventricular mass, diminished sleep disturbance and enhanced 
exercise capacity.1-7 Unfortunately in recent clinical trials, a proportion of patients exhibited 
complications such as fatal or nonfatal stroke, access thrombosis, increase in thrombotic 
events and exacerbation of malignancy associated with overly aggressive correction of 
anemia. 8-10 It is not established whether these complications are related to higher dose of 
EPO, underlying EPO resistance factors (i.e. inflammation) or achieving higher hematocrit 
(HCT). A multifactorial combination of predisposing circumstances is possible. A number of 
pharmacologic agents have been evaluated as adjuvant to ESAs therapy. These agents 
include iron, L-carnitine, ascorbic acid, androgens, statins, pentoxifylline and N-
acetylcysteine. In this review article we will focus on the agents that have been used in 
conjunction with EPO to correct anemia in patient with chronic kidney disease and end-
stage renal disease in an effort to reduce the dose requirement of EPO. 
2. Iron 
Iron is one of the most integral components of hematopoiesis in the anemia of kidney 
disease. “Trapped” iron storage or decreased availability of iron is the most common factor 
for the resistance to the effect of ESAs. Absolute iron deficiency is likely to be present in 
patients with CKD when: the percent transferrin saturation (plasma iron divided by total 
iron binding capacity x 100) falls below 20; the serum ferritin concentration is less than 100 
ng/mL among advance CKD(“predialysis”) and peritoneal dialysis patients and less than 
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200 ng/mL among home hemodialysis patients.11 However, functional iron deficiency is 
associated with transferrin saturation (TSAT) ≤20 percent and elevated ferritin levels 
(between approximately 200 to 800 ng/mL) or higher. An elevated ferritin level in this 
condition is likely secondary to the acute phase reaction of underlying inflammation. The 
2006 K/DOQI guidelines recommend goals of iron therapy during administration of ESAs. 
For predialysis and peritoneal dialysis patients: TSAT >20 percent or content of hemoglobin 
(Hb) in reticulocytes >29 percent and serum ferritin concentration >100 ng/mL. For patients 
undergoing hemodialysis: transferrin saturation >20 percent or content of Hb in 
reticulocytes >29 percent and serum ferritin concentration >200 ng/mL.12 
A number of clinical trials have compared which route of iron administration Intravenous 
(IV) vs Oral (PO) is superior in treating anemia of CKD. 13-22 
First we will discuss this issue in the Chronic Kidney Disease (CKD) population. 
3. Anemia in chronic kidney disease 
In a prospective trial by Stoves et.al, PO vs IV route of iron administration was studied. 
Forty five anemic patients with CKD, not on dialysis, were randomized to receive oral 
(ferrous sulfate 200 mg tid) or intravenous (300 mg iron sucrose monthly) iron therapy. EPO 
was started at the same time and the dose adjusted according to a pre-established protocol. 
After an average follow up of 5.2 months, there were no significant differences in Hb 
response and EPO dose between the two groups.13 A prospective study by Charytan et. al. 
in 96 CKD anemic patients on EPO compared the efficacy of IV iron (5 doses of 200 mg iron 
sucrose weekly) to oral iron (ferrous sulfate 325 mg tid). They found an increase in Hb and 
ferritin following IV iron, whereas the oral iron group demonstrated an increase in Hb 
without increase in iron stores.14 Both of the above studies failed to show IV iron superior to 
PO in either selected group of CKD patients. Van Wyck et.al. conducted a larger study of 
182 non dialysis-dependent CKD (stages 3 to 5) patients to compare oral iron vs. IV iron. 
That randomized, controlled, multicenter trial tested IV iron as sucrose 1 g in divided doses 
over 14 days vs oral ferrous sulfate 325 mg three times a day for 56 days. Inclusion criteria 
for the group were Hb ≤11 g/dL, TSAT ≤25%, and ferritin ≤300ng/mL. EPO/DPO dose was 
not changed for eight weeks prior to or during the study. The proportion of patients 
achieving the primary outcome (Hb increase ≥1 g/dL) was greater in the IV iron treatment 
group than in the oral iron treatment group (44.3% vs. 28.0%, P = 0.0344), as was the mean 
increase in Hb by day 42 (0.7 vs. 0.4 g/dL, P = 0.0298).15 Agarwal and colleagues conducted 
a randomized, multicenter, controlled trial in 75 adult, anemic, iron-deficient, non-dialysis 
CKD patients not receiving ESAs. The patients were randomly assigned to receive either IV 
ferric gluconate 250 mg weekly for 4 weeks or oral ferrous sulfate 325 mg three times a day 
for 42 days. Both oral and IV iron similarly increased Hb in anemic CKD patients not 
receiving ESAs.16  
A new IV iron preparation, ferumoxytol has been approved in the United States. 
It appears to be safe and effective when given as a rapid infusion of up to 510 mg in 
patients with CKD and patients on dialysis. A Phase III trial randomly assigned 304 
patients with CKD in a 3:1 ratio to two 510-mg doses of intravenous ferumoxytol within 5 
± 3 days or 200 mg of elemental oral iron daily for 21 days. Among patients who were not 
receiving ESAs, Hb increased 0.62 ± 1.02 g/dL with ferumoxytol vs. 0.13±0.93  
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g/dL with oral iron. Among patients who were receiving ESAs, Hb increased 1.16±1.49 
g/dL with ferumoxytol vs. 0.19±1.14 g/dL with oral iron. The increase in Hb at day 35, the 
primary efficacy end point, was 0.82+/-1.24 g/dL with ferumoxytol and 0.16+/-1.02 g/dL 
with oral iron (P<0.0001).17 The authors concluded that a regimen of two doses of 510 mg of 
intravenous ferumoxytol administered rapidly within 5±3 days was well tolerated and had 
the intended therapeutic effect. The side effects associated with IV iron in the above-
mentioned studies were headache, myalgia, and hypotension (particularly in thin, older 
women<65 kg). Intravenous iron sucrose has shown better tolerability. Oral iron has more 
GI associated side effects including constipation, diarrhea, nausea and vomiting.13-17 
As a result of these studies the K/DOQI guidelines have recommended that either oral iron 
therapy or intravenous iron therapy can be given in CKD patients. 
4. Anemia in end stage renal disease 
Among hemodialysis patients, studies show that transferrin saturation and serum ferritin 
levels usually continue to fall and anemia fails to correct despite ongoing oral iron therapy. 
MacDougall et.al. studied 37 iron-replete hemodialysis patients beginning EPO therapy 
randomized into three groups with different iron supplementation: Group1, IV iron dextran 
5 ml (equivalent to 250 mg of elemental iron) every 2 weeks; Group 2, oral ferrous sulfate 
200 mg tid; Group 3, no iron. Subjects were treated with 25 U/kg of EPO thrice weekly 
subcutaneously. After a period of 16 weeks, the Hb response in the group receiving IV iron 
(7.3+/-0.8 to 11.9+/-1.2 g/dL) was significantly greater than that for the other two groups 
(7.2 +/-1.1 to 10.2 +/-1.4 g/dL and 7.3+/-0.8 to 9.9+/-1.6 g/dL for Groups 2 and 3, 
respectively; p < 0.005 for both groups vs. Group 1 at 16 weeks). Serum ferritin levels 
remained constant in those receiving IV iron (345 +/-273 to 359+/-140 mcg/L) in contrast to 
the other two groups in which ferritin levels fell significantly (309+/-218 to 116+/- 87 
mcg/L and 458+/-206 to 131+/- 121 mcg/L for Groups 2 and 3, respectively; p < 0.0005 for 
Group 1 vs. Group 2, and p < 0.005 for Group 1 vs. Group 3 at 16 weeks). Dosage 
requirements of EPO were also less in Group1.These results suggested that even in iron-
replete patients, those supplemented with IV iron have an enhanced Hb response to EPO 
with better maintenance of iron stores and lower dosage requirements of EPO.18  
Wingard et.al. conducted a prospective study on 46 EPO treated hemodialysis patients and 
randomized them into four different oral iron preparations. These four preparations 
included Chromagen (ferrous fumarate from Savage Laboratories), Feosol (ferrous sulphate 
from Smith Kline Beecham), Niferex (polysaccharide, Central Pharmaceutical) or Tabron 
(ferrous fumarate; Parke-Davis). All patients were prescribed approx 200 mg of elemental 
iron daily with at least 100 mg of ascorbic acid for six months. The study concluded that 
with emphasis on compliance, oral iron supplementation at the dose used for this study was 
able to maintain adequate iron status in the short term (less than 6 months) without the need 
for IV iron dextran. However, IV iron dextran eventually (after 6 months) would be 
necessary because of the downward trend in iron stores.19  
Ferumoxytol was studied in a randomized, open-label, controlled, multicenter Phase 3 trial 
by Provenzano et.al. to evaluate the safety and efficacy of IV ferumoxytol compared with 
oral iron.20 Anemic patients on HD and on a stable ESA regimen received either two 
injections of 510 mg of ferumoxytol within 7 days (n = 114) or 200 mg elemental oral iron 
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daily for 21 days (n = 116). Ferumoxytol resulted in a mean increase in Hb of 1.02+/-1.13 
g/dL at day 35 compared with 0.46+/-1.06 g/dL with oral iron (p = 0.0002). There was a 
greater mean increase in TSAT with ferumoxytol compared with oral iron at day 35 (p < 
0.0001). 
5. Conclusion 
For patients with chronic kidney disease who are not on dialysis, oral iron or IV iron can be 
used for iron supplementation. This conclusion is consistent with the opinion of the Work 
Group from K DOQI guidelines. 
The preferred route of administration of iron in patients with chronic kidney disease on 
hemodialysis is intravenous as supported by K DOQI guidelines as of 2006. 
6. Ascorbic acid 
Vitamin C or ascorbic acid has been studied in the metabolism of iron and anemia 
management. The first studies were performed in guinea-pigs. It was found that ascorbic 
acid deprivation increased the total non-haem iron concentration in the spleen and reduced 
it in the liver, and in both organs ferritin was diminished and haemosiderin increased. 
Repleting the ascorbic acid restored the normal distribution of iron between the two storage 
compounds, and in the spleen the total storage iron concentration returned to control levels 
within 24 hours.21 Another important property of ascorbic acid is its ability to increase the 
availability of storage iron to chelators.22 In hemodialysis patients this role of ascorbic acid 
was investigated by Deicher who conducted a cross-sectional, single-centre observational 
study. Pre-dialysis plasma Vitamin C concentrations were measured and response to EPO 
(Hb concentration/ international units EPO/kg/week) was recorded. Univariate analysis 
yielded a significant correlation between Vitamin C plasma levels and response to EPO. It 
was found that in unselected hemodialysis patients Vitamin C plasma levels account, at 
least partially for the response to EPO.23 That work led to ascorbic acid investigations for use 
in EPO-treated hemodialysis patients, particularly those with EPO- hypo responsiveness, 
elevated serum ferritin levels, and functional iron deficiency (transferrin saturation ≤20 
percent and elevated ferritin level between 200 to 800 ng/ml or higher). Studies evaluated 
the role of IV Vitamin C in hemodialysis patients and showed that in those patients who 
develop resistance to EPO with “functional iron deficiency”, the resistance can be overcome 
by giving Vitamin C instead of iron,thus avoiding hemosiderosis.24 In another comparative 
larger study, Tarng et.al. were able to show similar results in a prospective trial of dialysis 
patients. Sixty-five HD patients with serum ferritin levels greater than 500 mcg/L were 
recruited and divided into the control (N = 19) and intravenous ascorbic acid IVAA (N = 46) 
groups. IVAA patients with a hematocrit (HCT) of less than 30% received 300 mg of ascorbic 
acid three times per week for eight weeks. Controls had a HCT of more than 30% and did 
not receive the adjuvant therapy. Red blood cell and reticulocyte counts, iron metabolism 
indices, erythrocyte zinc protoporphyrin (E-ZPP), and the concentrations of plasma 
ascorbate and oxalate were examined before and following the therapy. Thirteen patients 
(four controls and nine IVAA patients) withdrew by the end of the study. Eighteen patients 
had a dramatic response to IVAA with a significant increase in Hb and reticulocyte index 
and a concomitant 24% reduction in EPO dose after eight weeks. This paralleled a 
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significant rise in serum iron and TSAT and a fall in E-ZPP and serum ferritin (baselines vs. 
8 weeks, serum iron 68+/-37 vs. 124 +/-64 mcg/dL, TSAT 27+/-10 vs. 48+/-19%, E-ZPP 
123+/-44 vs. 70+/-13 micromol/mol heme, and serum ferritin 816+/-435 vs. 587+/-323 
mcg/L, p<0.05). Compared with responders, mean values of Hb, EPO dose, iron 
metabolism parameters, and E-ZPP showed no significant changes in controls (N = 15) and 
in non-responders (N = 19).25  
A single PO study by Benz et. al. was conducted in 21 EPO resistant anemic hemodialysis 
patients with ferritin levels greater than 350 ng/mL had received oral daily ascorbic acid at 
a dose of 500 mg/day and were retrospectively studied. Hemoglobin, HCT, EPO dose, 
ferritin, and transferrin saturation were recorded at baseline and after three months of 
treatment. EPO dose/HCT was calculated. Serum oxalate levels were also measured. In this 
study, daily oral ascorbic therapy decreased ferritin levels and EPO dose requirements 
while raising Hb and HCT level. Hb increased 9% from 11.4 to 12.2 gm/dl (p = 0.05), HCT 
increased 10% from 33.3 to 36.7% (p = 0.05), and EPO dose requirement decreased 33% from 
26,229 to 17,559 U/week (p = 0.03). Ferritin levels decreased 21% from 873 to 691 ng/mL (p = 
0.004) Patients with oxalate levels >27 micromol/L were instructed to stop ascorbic acid 
treatment, and mean levels decreased from 107 to 19 micromol/L (p = 0.01) over a mean 
time of 71 days. This beneficial profile of the effects of ascorbic acid therapy is consistent 
with improvement of EPO resistance and cost savings in this population.26 
The primary concern for using Vitamin C in dialysis patients is secondary oxalosis because 
of the impairment in renal excretion and inadequate removal by dialysis procedures.27-28 
Tarng et.al. showed that oxalate levels increase modestly after 8 weeks of IV Vitamin C but 
information on longer courses of treatment is limited.25 Canavese prospectively studied the 
dose of Vitamin C and effect on oxalate levels in 30 dialysis patients. Eighteen patients were 
administered intravenous ascorbate during 18 months (250 mg/wk, subsequently increased 
to 500 mg), and 12 patients were taken as reference untreated cases. The study found that 
plasma oxalate levels progressively increased as the dose of IV Vitamin C was increased 
from 250 to 500 mg/week. After six months at a dose of 500 mg per week, 7 of 18 patients 
(40 percent) attained plasma oxalate levels that exceeded the range that would be associated 
with calcium oxalate super saturation at usual calcium concentrations.29 
The 2006 K/DOQI guidelines for anemia in CKD stated that there was insufficient evidence 
to recommend Vitamin C as an adjuvant to EPO therapy.30 However, several of the clinical 
studies were published subsequent to the development of those guidelines. 
7. Pentoxifylline 
Pentoxifylline (PTX) is a methyl xanthine derivative, which is approved for use in 
peripheral vascular disease and may also have anti-inflammatory effects according to 
studies. Benbernou et. al. studied pentoxifyline and examined its regulatory effect on T 
helper (TH1-and TH2) cell-derived cytokines in human whole blood and peripheral blood 
mononuclear cells stimulated with phytohemagglutinin and phorbol myristate acetate. 
The results showed that PTX at the appropriate concentrations (5 x 10(-4)M ) could induce 
selective suppression of interleukin (IL) -2 and interferon (INF) -gamma, whereas at high 
concentrations this drug could act as a suppressive agent of both TH1- and TH2-derived 
cytokines.31 Bienvenu showed similar results that PTX possesses a much broader spectrum  
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of activity on cytokine production than was initially described, and it appears to be a 
potential and promising immunotherapeutic agent.32 These studies led to PTX’s possible 
role in treating EPO resistant anemia. Navarro et. al. conducted a prospective small study 
of 7 anemic patients with CKD, who were treated with pentoxifylline (400 mg orally 
daily) for 6 months with the goal of defining the effects of pentoxifylline, as an agent with 
anti-tumor necrosis factor (TNF)-alpha properties. The results showed Hb significantly 
increased in the pentoxifylline-treated patients at the 6th month (9.9+/-0.5 g/dL at 
baseline;10.6+/-0.6 g/dL at the 6th month, respectively, p < 0.01), whereas no increase 
was seen in the control group. Serum EPO levels remained stable in all patients. However, 
the serum TNF-alpha concentration decreased significantly in patients receiving 
pentoxifylline. The study suggested that the inhibition of erythropoiesis by cytokines may 
play a significant role in renal anemia. The administration of agents with anti-cytokine 
properties, such as pentoxifylline, can improve the hematologic status in this 
population.33 Another small study was conducted by Cooper and colleagues on 16 
dialysis EPO resistant anemic patients. The patients were treated with oral pentoxifylline 
400 mg daily for 4 months. Ex-vivo T cell generation of TNF-alpha and IFN-gamma from 
the patients was assessed before and 6 to 8 weeks after the therapy. A total of 12 of 16 
patients completed the study. Before therapy, mean Hb concentration was 9.5+/-0.9 g/dL. 
After 4 months, the mean Hb concentration increased to 11.7+/-1.0 g/dL (p = 0.0001). 
Baseline ex vivo T cell expression of TNF-alpha decreased from 58% +/-11% to 31%+/-
23% (p= 0.0007) after therapy. Likewise, IFN-gamma expression decreased from 31%+/-
10% to 13%+/-10% (p = 0.0002). EPO doses remained unchanged in all but one patient in 
whom the dose was reduced in response to a higher Hb. One patient who was previously 
transfusion dependent was able to stop receiving monthly transfusions. Pentoxifylline 
therapy may significantly improve Hb response in patients with EPO–resistant anemia in 
renal failure.34 
This small, open-label, uncontrolled study suggests the need for a larger, controlled trial 
with this agent. Until such a trial is conducted, pentoxifylline is not recommended as an 
EPO-adjuvant except in the experimental setting. 
8. Statins 
Statins (HMG-CoA reductase inhibitors) are a class of drugs used to lower cholesterol levels 
by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production 
of cholesterol in the liver. As mentioned above, cytokines play a role in inhibition of 
erythropoiesis. Statins have been evaluated as an adjuvant to EPO with the thought that 
they have anti-oxidant and anti-inflammatory properties. In one retrospective study, 70 HD 
patients were treated with statins for a period of 4.7 months and were found to have the 
mean Hb level rise from 10.6 to 12.5 g/dL (p < 0.0005) with an associated 25 percent 
decrease in EPO requirements.35 Another study investigated whether the anti-inflammatory 
effect of statins improved EPO responsiveness in hemodialysis patients. It examined 
patients with Type 2 diabetes mellitus, who had been shown to have EPO resistance. One 
hundred and three patients were stratified into statin and non-statin groups.The outcome of 
interest was EPO dose. The mean EPO dose (units/kg per week) was significantly lower in 
the statin group (275.6 ± 273.2, vs. 449.5 ± 555.9, p < 0.05). Twenty percent of patients in the  
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statin group required EPO dose in excess of an EPO equivalent of 500 units/kg per week, 
compared to 30.88% in the non-statin group. The two-way analysis of variance showed no 
interaction between the use of statins and the presence of Type 2 diabetes mellitus on EPO 
dose. This study demonstrated that hemodialysis patients who were on statins had a 
significantly lower EPO requirement. This association is possibly due to the pleiotropic 
effect of statins.36 
A prospective study tested the effect of statin therapy on ESA hypo- responsiveness, and 
emphasized its anti-inflammatory benefits in maintenance hemodialysis patients. This study 
enrolled 30 patients with baseline cholesterol >220 mg/dL. Low-dose atorvastatin (10 
mg/day) was prescribed for 12 weeks. They prospectively recorded biochemistry and 
hematological profiles, ESAs prescription and inflammatory markers at baseline, 4 weeks 
and 12 weeks. Statistically significant changes were noted after 4 and 12 weeks of statin 
therapy for cholesterol (272.5 to 184.4 and 196.4 mg/dL, p < 0.05) and ESA hypo- 
responsiveness, reported as EPO to HCT ratio (EHR) (129.3+/-58.2 to 122.3+/-53.5 and 
121.0+/-53.3 EPO U/HCT/week, p < 0.05). Mean values for proinflammatory cytokines 
included interleukin-6 and TNF-alpha levels decreased by 30.8 and 10.6%, respectively. 
These data suggest that statin therapy may benefit patients with ESA hypo-responsiveness. 
This benefit in ESA hypo-responsiveness is associated with the effects of statins on 
inflammation.37 
These preliminary studies may justify future studies to use statins as an EPO dose reducing 
adjuvant in patients with inflammation-mediated EPO resistant anemia of CKD. 
9. Carnitine 
L-carnitine is a small molecule (molecular weight: 161.2) that is derived from dietary 
products, mainly red meat and milk. Endogenous carnitine production takes place in the 
liver from lysine, methionine, ascorbate, niacin and pyridoxine. L-carnitine is required for 
the transport of long-chain fatty acids into the mitochondria and is an integral part of energy 
metabolism via ATP formation.  
L-carnitine has been shown to improve anemia in uremic patients by stabilizing erythrocyte 
membrane function or erythropoiesis. End-stage renal disease patients are known to have 
carnitine deficiency.38 This could be a contributing factor of anemia requiring higher dose of 
EPO. Thus, it has been used therapeutically in dialysis patients with and without 
concomitant EPO. Carnitine’s role as an adjuvant to EPO in kidney disease is unclear. Most 
studies have involved HD patients with IV carnitine administration. 
A 2002 meta-analysis evaluated the efficacy of IV carnitine supplementation in lowering the 
required dose of EPO using data from six randomized trials. The EPO dose was found to be 
significantly lower among those administered carnitine, with a beneficial response reported 
in four of the six studies.38 Two studies showed improvement in Hb and HCT with PO 
carnitine but they were published before EPO was available.39,40 In one study, 24 dialysis 
anemic patients were divided into two groups, controls (inert placebo), treated patients (L-
carnitine 1.6 g PO daily) for one year. A significant increase in HCT, Hb, red cell count and 
mean corpuscular Hb concentration was observed. In comparison with the control group, an 
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early improvement could be detected by the 3rd month, with further increases in the 
successive months of treatment in the L-carnitine cohort. 
There is some evidence in the literature suggesting that accumulation of metabolites 
(trimethyleamine and trimethylamines-N-oxide)of oral carnitine, may have potential 
toxicity41. Marcus et.al. conducted a study using oral carnitine and showed that a small dose 
of L-carnitine is sufficient to increase the blood concentration of carnitine.41 The concern 
remains about the accumulation of trimethylamines-N-oxide and its potential toxicologic 
effects include neurological toxicity and uremic breath. 
The 2006 K/DOQI guidelines for anemia in CKD stated that there was insufficient evidence 
to recommend L-carnitine.42 
10. Androgens 
There is no literature available in CKD patients not on dialysis. Before EPO was available, 
androgens (which may increase endogenous EPO production, sensitivity of erythroid 
progenitors to the effects of EPO, and red blood cell survival) were used regularly in the 
treatment of anemia in dialysis patients.43-46 Their use for anemia in dialysis patients has 
declined markedly since EPO was approved.  
EPO and androgen’s combination in hemodialysis patients has been studied: 
Ballal et.al. performed a study in a group of 15 adult male hemodialysis patients.47 Seven 
patients were treated with EPO alone at a dose of 2,000 U intravenously (IV) three times a 
week. An additional group of eight patients was treated with 2,000 U of EPO three times a 
week and also received 100 mg of nandrolone decanoate intramuscularly (IM) each week. 
After 12 weeks of therapy, HCT values increased slightly in the group receiving EPO alone, 
from 25.3+/-0.8 to 27.4+/-1.5. In contrast, EPO in combination with nandrolone decanoate 
resulted in a greater increase in HCT values, from 24.4+/-1.4 to 32.9 +/-1.8 (p < 0.001). The 
results showed that the groups receiving low-dose EPO alone had a poor erythropoietic 
response. In contrast, patients receiving androgen in addition to EPO had a significantly 
greater increase in HCT values with treatment. These data show that androgen therapy 
significantly augments the action of exogenous EPO such that lower doses of EPO may be 
sufficient for an adequate hematopoietic response. 
In a prospective, randomized study by Berns et al. in a chronic hemodialysis population, 
patients received EPO 40 U/kg intravenously three times weekly either alone (Group 1, n = 
6) or with weekly intramuscular injection of 2 mg/kg nandrolone decanoate (Group 2, n = 6) 
for up to 16 weeks. Baseline HCT, ferritin, N-terminal parathyroid hormone, and aluminum 
levels were similar. The mean weekly rate of rise in HCT was 0.32+/-0.13% in Group 1 and 
0.37+/-0.11% in Group 2, (p = NS). Three of 6 patients in Group 1, but only 1 of 6 patients in 
Group 2, reached the target HCT of 30% within 16 weeks. Two patients in Group 2 
requested that the nandrolone decanoate be stopped prior to reaching target HCT because 
of unacceptable side effects (acne). 48 Nandrolone decanoate did not enhance the response 
rate to this EPO dose and is associated with significant side effects. 
In a longer open-label study with low-dose EPO therapy, 19 chronic hemodialysis patients 
were randomly assigned to receive EPO (1,500 units IV at each HD treatment) either alone 
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or with nandrolone decanoate (100 mg intramuscularly weekly) for 26 weeks.49 The mean 
increase in HCT and the final achieved HCT were greater in the nandrolone decanoate 
treated group (8.2 and 33.2 percent, respectively) than in the group treated with EPO alone 
(3.5 percent and 28.3 percent, respectively). No serious side effects were reported. 
Thirty two hemodialysis patients were randomly assigned to receive low dose EPO therapy 
(1,000 units SC at each HD treatment) either alone or with nandrolone decanoate 50 mg 
intramuscularly twice weekly for six months.50 The increase in Hb in the 
nandrolone decanoate treated group (from 7.5 to 10.4 g/dL) was not statistically different 
from the control group (7.3 to 10.0 g/dL). Side effects, including gynecomastia, hirsutism, 
menstrual irregularity, and increases in liver enzymes and triglyceride levels, were 
common. 
The limiting factor in these studies was small size and relatively short follow ups, and none 
attempted to maintain currently recommended Hb levels. The 2006 K DOQI guidelines for 
anemia in CKD stated that androgens should not be used as an adjuvant to EPO. 
11. N-acetylcysteine 
N–acetylcysteine (NAC) is a drug and nutritional supplement used primarily as a mucolytic 
agent and also in the management of acetaminophen overdose. To explore the efficacy of 
oral NAC supplementation for anemia and oxidative stress in hemodialysis patients, Chien 
et al studied 325 dialysis patients. In this study, 49 pateints received NAC 200 mg orally 
three times a day during the first 3 months of dialysis, while the other 276 patients not 
receiving NAC were observed. During the 4-month study, 11 patients receiving NAC 
withdrew but had no severe adverse effects, while 49 patients not receiving NAC had 
negative confounding events. Thus only the data of the remaining patients, 38 taking NAC 
and 227 not taking NAC, were analyzed for efficacy. 
When the EPO dosage was stable, only the NAC group had a significant increase in HCT, 
accompanied with a decrease in plasma levels of 8-isoprostane and oxidized low-density 
lipoprotein. Analyzed as a nested case-control study, NAC supplementation was also found 
to be a significant predictor of positive outcomes in uremic anemia. 51 To determine the 
contribution of injectable iron administered to hemodialysis patients in causing oxidative 
stress and the beneficial effect of NAC in reducing it, Swarnalatha et al conducted a 
prospective, double blinded, controlled, cross over trial on 14 adult hemodialysis patients 
who were randomized into two groups; one group received NAC in a dose of 600 mgs by 
mouth twice daily for 10 days prior to intravenous iron therapy and the other group 
received placebo. Both groups received intravenous iron therapy, 100 mg of iron sucrose in 
100 mL of normal saline given over a period of one hour. Blood samples for the markers of 
oxidative stress were taken before and after the iron therapy. After a week of wash-out 
period for the effect of NAC, subjects crossed over to the opposite regimen. They measured 
the lipid peroxidation marker, malondiaaldehyde (MDA), to evaluate the oxidative stress 
and total anti-oxidant capacity (TAC) for the antioxidant level in addition to the highly 
sensitive C-reactive protein (HsCRP). Non-invasive assessment of endothelial dysfunction 
was measured by digital plethysmography before and after intravenous iron therapy. There 
was an increase of MDA (21.97 + 3.65% vs 7.06 + 3.65%) and highly sensitive C-reactive 
protein (HsCRP) (11.19 + 24.63% vs 13.19 + 7.7%) after iron administration both in the 
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placebo and the NAC groups. NAC reduced the baseline acute systemic generation of 
oxidative stress when compared to placebo, which was statistically significant with MDA 
(12.76 +/-  4.4% vs 9.7 +/- 4.4%) but not with HsCRP. Pre-treatment with NAC reduced the 
endothelial dysfunction when compared to placebo, but it was not statistically significant.  
The author concluded that in those HD patients, NAC reduced the oxidative stress before 
and after the administration of intravenous iron therapy in addition to the endothelial 
dysfunction induced by this treatment. 52 
Finnigan and Benz reported the results of treating 12 ESRD EPO resistant hemodialysis 
subjects with oral NAC 600 mg by mouth twice daily for 6 months. In that small pilot study, 
NAC therapy was associated with a 53% reduction in the EPO Resistance Index (weekly 
EPO dose/weight in Kg/Hb). 53  
These preliminary studies suggest the need for a larger, controlled trial with NAC. Until 
then, routine use of NAC as an EPO- adjuvant cannot be recommended. 
12. Discussion 
Anemia of CKD/ESRD has multiple etiologies, although the decrease in EPO production by 
the diseased kidneys is the major contributor. Recently, studies targeting higher Hb levels or 
using higher EPO dosing regimens in the correction of anemia have shown detrimental 
effects including increased all cause mortality, cardiac and cerebral vascular events and 
vascular access thrombosis8-10,54 It is not clear whether this is due to higher HCT or EPO the 
molecule itself at higher concentration. This review article focused on adjuvant oral and 
parenteral agents that have been used along with EPO to reduce its dose and give 
foundation to research in randomized control trials. There may also be a potential benefit of 
these agents to use along with EPO in reducing cost and expenditures especially when the 
bundling method of dialysis payment is in effect. 
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